# MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)

> **NCT03846219** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Immunic AG** · enrollment: 210 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis (RRMS)

## Interventions

- **DRUG:** IMU-838 (30 mg/day)
- **DRUG:** IMU-838 (45 mg/day)
- **DRUG:** Placebo
- **DRUG:** IMU-838 (10 mg/day)

## Key facts

- **NCT ID:** NCT03846219
- **Lead sponsor:** Immunic AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-28
- **Primary completion:** 2020-04-24
- **Final completion:** 2029-12
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03846219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03846219, "MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03846219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*